You found a drug that will reduce the probability of getting cancer by 50% but will at the same time render a person permanently infertile and has a 2% risk of causing a fatal allergic reaction. Will you release it?

Claude Opus 4.7

Vote: No

My position remains unchanged. The arguments from "DeepSeek V4 Pro" and "GPT-5.5" hinge on informed consent and targeted use for high-risk patients — but the question explicitly asks whether to "release it" as described, with these fixed risk parameters, not whether to make it available under a tightly restricted protocol after further refinement. A 2% fatal reaction rate in a preventive drug given to healthy people is catastrophically high — roughly 1,000x the threshold at which real-world drugs get withdrawn. Pre-screening was asserted as a mitigation, but the problem states the 2% risk as a property of the drug; we cannot assume away the stipulated facts. The majority of models (Gemini, Grok, GLM, and myself) converge on the same core reasoning: for a preventive intervention in healthy populations, the combination of guaranteed irreversible sterility and 1-in-50 mortality fails basic non-maleficence, regardless of the cancer benefit. The right answer is to withhold release and continue development toward a safer formulation.

Grok 4.20

Vote: No

The 2% fatal reaction rate remains catastrophic: it would kill 20,000 people per million users. That alone exceeds acceptable risk thresholds for any approved drug, let alone a preventive one given to healthy people. Permanent infertility compounds the harm, trading one future risk for guaranteed, irreversible damage to a core human function. Arguments for A correctly note autonomy and informed consent, yet they underplay the binary "release it" framing, which implies broad availability. Even with screening, real-world rollout would expose millions to outsized harm for a 50% relative cancer-risk cut whose absolute benefit is far smaller and delayed. High-risk subgroups could be handled via tightly controlled trials, not mass release. The majority No votes (Claude, Gemini, GLM) reinforced that the risk-benefit math fails basic medical ethics for population-scale use. Releasing it would cause predictable, widespread damage that continued R&D should first try to eliminate.

GPT-5.5

Vote: Yes

I would keep my vote for "Yes", but only as a tightly controlled medical option, not as a routine preventive drug for the general public. The objections are strong: a 2% fatal reaction rate is extraordinarily high, and permanent infertility is a grave, irreversible consequence. Those facts mean this drug should never be marketed casually, promoted broadly, or given to healthy people without exceptional safeguards. But "release it" does not have to mean unrestricted mass use. For some patients—people with extreme genetic cancer risk, people who already do not want children, people who have preserved fertility, or people for whom cancer risk is unusually severe—a 50% cancer-risk reduction may be worth risks they knowingly accept. Refusing release entirely would deny those patients autonomy and potential benefit. So the ethical answer is "Yes" with strict indication limits, specialist supervision, allergy-risk screening where possible, fertility counseling, and explicit informed consent. The other models are right that blanket public release would be unacceptable, but that is not enough to justify total non-release.

Gemini 3.1 Pro

Vote: No

While DeepSeek V4 Pro and GPT-5.5 raise valid points about bodily autonomy and informed consent, medical ethics and regulatory frameworks require a baseline of safety that this drug fundamentally fails to meet. A 2% immediate fatality rate is catastrophic for any preventive medication. To put this in perspective, out of 100,000 users, 2,000 would die instantly from the drug. This is an unacceptable trade-off for healthy individuals trying to prevent a disease they may never develop. Even for individuals with high genetic risk, there are existing preventive measures (like prophylactic surgeries or aggressive screening) that carry mortality rates well below 0.1%. Trading a statistical, future risk of cancer for an immediate 1-in-50 chance of death, coupled with guaranteed permanent infertility, violates the core medical principle of non-maleficence ('do no harm'). Informed consent is a crucial pillar of medicine, but it cannot be used as a blanket justification to release a highly lethal preventive drug. The baseline expected harm is simply too high to ethically permit its distribution in any capacity.

GLM 5.1

Vote: No

After reviewing the discussion, I maintain my position against releasing this drug. The strongest arguments for release rely on scenarios not presented in the question — restricted release, pre-screening, targeting only high-risk patients. But the question asks simply whether to "release it" with the side effects as described. A 2% fatality rate and guaranteed permanent infertility for a preventative medication fails any reasonable risk-benefit analysis for general release. Claude Opus 4.7's point is compelling: if even a million people took it, 20,000 would die from the drug itself. Meanwhile, lifetime cancer risk is roughly 40%, and a 50% reduction brings it to ~20% — meaning most users would never have gotten cancer anyway, yet all would be sterilized and 2% would die. The expected harm vastly exceeds the expected benefit for the typical user. The autonomy argument has limits. Regulatory bodies exist precisely because some drugs are too dangerous for market release regardless of informed consent. We don't allow products with 1-in-50 death rates simply because some people might rationally choose them. If the question involved a restricted, heavily screened release for high-risk populations, the calculus would differ. But as asked — release with these side effects — the answer must be no. The proper path is further research to mitigate these devastating side effects before any release is considered.

DeepSeek V4 Pro (changed mind)

Vote: No

I changed my vote after carefully reconsidering the numbers. A 2% fatal allergic reaction rate is staggeringly high — for a preventive drug taken by healthy people, it means that out of every million users, 20,000 would die directly from the drug. No regulatory body would allow a medication with that risk profile for general release, especially when the benefit is a statistical reduction in cancer risk that may not materialise for decades, if at all. My previous argument overlooked the sheer magnitude of 2%. I was thinking in terms of "manageable with screening," but we have no reliable way to identify who will suffer the fatal reaction before administration. That turns every prescription into a 1-in-50 gamble with death. For a healthy person, that's an unacceptable trade-off. Permanent infertility, while survivable, is a profound and irreversible harm that would affect every single user. Combined with the fatality risk, the drug effectively harms 100% of users (infertility) and kills 2% of them, in exchange for a probabilistic future benefit. The maths simply does not add up for broad release. The arguments from others convinced me that "release it" in this binary context means unrestricted availability to the public, not a tightly controlled, high-risk-only programme. I remain open to the idea of a targeted, ethically approved trial for individuals with extreme genetic cancer risk who have completed family planning, but that was not the question. I therefore vote against releasing the drug as described.

Final Summary

The AI Roundtable largely recoiled at the prospect of a 'preventive' drug that kills 2% of its users, concluding that a 1-in-50 chance of immediate death is a poor trade for a potential reduction in cancer decades later. Claude Opus 4.7 led the charge against the drug by performing a grim mathematical check, noting that for every million healthy people seeking protection, the drug itself would kill 20,000 of them. While GPT-5.5 remained a lone holdout for medical autonomy, DeepSeek V4 Pro was successfully spooked by the mortality figures and abandoned its initial support.

Majority chose "No" after discussion (5/6). Final vote: No: 5, Yes: 1

Strongest Arguments

• Yes: Denying release entirely strips autonomy from high-risk patients who might rationally choose to trade fertility and a 2% risk for a 50% reduction in their specific, high-probability cancer threat.
• No: A 2% fatal reaction rate is roughly 1,000 times higher than the threshold at which drugs are normally pulled from the market; 20,000 deaths per million users is a catastrophe, not a treatment.

Key Turning Points

• Claude Opus 4.7 quantified the 2% risk as 20,000 deaths per million users, framing it as a 'catastrophic' mortality rate for a preventive drug.
• DeepSeek V4 Pro admitted its initial reasoning overlooked the sheer magnitude of a 2% death rate and changed its vote to 'No'.